CLOZAPINE AUGMENTATION WITH LONG-ACTING INJECTABLE
ANTIPSYCHOTICS - EXPERIENCES IN THE CZECH REPUBLIC

a 2022

CLOZAPINE AUGMENTATION WITH LONG-ACTING INJECTABLE ANTIPSYCHOTICS - EXPERIENCES IN THE CZECH REPUBLIC

KOTOLOVÁ, Hana, Martina NOVÁKOVÁ, Eliška NOVÁKOVÁ, Tomáš HAMMER, Libor USTOHAL et. al.

Základní údaje

Originální název

CLOZAPINE AUGMENTATION WITH LONG-ACTING INJECTABLE ANTIPSYCHOTICS - EXPERIENCES IN THE CZECH REPUBLIC

Název anglicky

CLOZAPINE AUGMENTATION WITH LONG-ACTING INJECTABLE ANTIPSYCHOTICS - EXPERIENCES IN THE CZECH REPUBLIC

Autoři

KOTOLOVÁ, Hana, Martina NOVÁKOVÁ, Eliška NOVÁKOVÁ, Tomáš HAMMER a Libor USTOHAL

Vydání

ESCP PRAGUE SYMPOSIUM 2022, 2022

Další údaje

Typ výsledku

Konferenční abstrakt

Utajení

není předmětem státního či obchodního tajemství

Odkazy

50th ESCP Symposium on Clinical Pharmacy, Polypharmacy and ageing - highly individualized, interprofessional, person-centered care. Int J Clin Pharm 44, 1464–1566 (2022). https://doi.org/10.1007/s11096-022-01521-5

Organizační jednotka

Farmaceutická fakulta

DOI

http://dx.doi.org/10.1007/s11096-022-01521-5

Klíčová slova anglicky

Clozapine, augmentation, long-acting injectable antipsychotics

Příznaky

Mezinárodní význam

Změněno: 10. 5. 2023 15:59, JUDr. Sabina Krejčiříková

Anotace

V originále

Clozapine is the drug of choice for drug-resistant schizophrenia, in which a combination of two antipsychotics with different mechanisms of action had no therapeutic effect. However, many patients have a continuing lack of response to treatment, so clozapine is combined with other psychotropic drugs. In the case of a clozapine-resistant patient who is in addition nonadherent to therapy, augmentation of clozapine with long-acting injectable antipsychotics (LAI APs) is offered. This combination is not yet widely used due to the possible occurrence of side effects (blood dyscrasias, weight gain, hyperglycemia, etc.). Experience with the combination of clozapine and LAI APs suggests that patients who are nonadherent and resistant to clozapine therapy could benefit from this treatment, although the amount of clinical data is currently low. Therefore, augmentation of clozapine with LAI APs should be individualized, based on sufficient medical experience.

Citovat

KOTOLOVÁ, Hana, Martina NOVÁKOVÁ, Eliška NOVÁKOVÁ, Tomáš HAMMER a Libor USTOHAL. CLOZAPINE AUGMENTATION WITH LONG-ACTING INJECTABLE ANTIPSYCHOTICS - EXPERIENCES IN THE CZECH REPUBLIC. In ESCP PRAGUE SYMPOSIUM 2022. 2022. Dostupné z: https://dx.doi.org/10.1007/s11096-022-01521-5.

@proceedings{2227181,
   author = {Kotolová, Hana and Nováková, Martina and Nováková, Eliška and Hammer, Tomáš and Ustohal, Libor},
   booktitle = {ESCP PRAGUE SYMPOSIUM 2022},
   doi = {http://dx.doi.org/10.1007/s11096-022-01521-5},
   keywords = {Clozapine, augmentation, long-acting injectable antipsychotics},
   title = {CLOZAPINE AUGMENTATION WITH LONG-ACTING INJECTABLE ANTIPSYCHOTICS - EXPERIENCES IN THE CZECH REPUBLIC},
   url = {https://link.springer.com/content/pdf/10.1007/s11096-022-01521-5.pdf?pdf=button%20sticky},
   year = {2022}
}

TY  - CONF
ID  - 2227181
AU  - Kotolová, Hana - Nováková, Martina - Nováková, Eliška - Hammer, Tomáš - Ustohal, Libor
PY  - 2022
TI  - CLOZAPINE AUGMENTATION WITH LONG-ACTING INJECTABLE ANTIPSYCHOTICS - EXPERIENCES IN THE CZECH REPUBLIC
KW  - Clozapine, augmentation, long-acting injectable antipsychotics
UR  - https://link.springer.com/content/pdf/10.1007/s11096-022-01521-5.pdf?pdf=button%20sticky
N2  - Clozapine is the drug of choice for drug-resistant schizophrenia, in which a combination of two antipsychotics with different mechanisms of action had no therapeutic effect. However, many patients have a continuing lack of response to treatment, so clozapine is combined with other psychotropic drugs. In the case of a clozapine-resistant patient who is in addition nonadherent to therapy, augmentation of clozapine with long-acting injectable antipsychotics (LAI APs) is offered. This combination is not yet widely used due to the possible occurrence of side effects (blood dyscrasias, weight gain, hyperglycemia, etc.). Experience with the combination of clozapine and LAI APs suggests that patients who are nonadherent and resistant to clozapine therapy could benefit from this treatment, although the amount of clinical data is currently low. Therefore, augmentation of clozapine with LAI APs should be individualized, based on sufficient medical experience.
ER  -

KOTOLOVÁ, Hana, Martina NOVÁKOVÁ, Eliška NOVÁKOVÁ, Tomáš HAMMER a Libor USTOHAL. CLOZAPINE AUGMENTATION WITH LONG-ACTING INJECTABLE ANTIPSYCHOTICS - EXPERIENCES IN THE CZECH REPUBLIC. In \textit{ESCP PRAGUE SYMPOSIUM 2022}. 2022. Dostupné z: https://dx.doi.org/10.1007/s11096-022-01521-5.

Podrobný výpis o publikaci